Cargando…
Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension
BACKGROUND: Overweight and obesity are common among patients with Cushing’s syndrome (CS) and may persist in some patients even after ostensibly curative surgery, contributing to cardiometabolic dysfunction and increased cardiovascular risk. Mifepristone, a selective glucocorticoid receptor antagoni...
Autores principales: | Fein, Henry G., Vaughan, T. Brooks, Kushner, Harvey, Cram, David, Nguyen, Dat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624667/ https://www.ncbi.nlm.nih.gov/pubmed/26507877 http://dx.doi.org/10.1186/s12902-015-0059-5 |
Ejemplares similares
-
THU621 Mifepristone In Exogenous Cushing's Syndrome
por: Priyadarshan, Swetha, et al.
Publicado: (2023) -
SUN-460 Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
por: Moraitis, Andreas, et al.
Publicado: (2019) -
Hypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome
por: Sai, Katta, et al.
Publicado: (2019) -
Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing’s Syndrome
por: Díaz-Castro, Francisco, et al.
Publicado: (2020) -
Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016)